A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment
Latest Information Update: 09 Jan 2026
At a glance
- Drugs Bifikafusp alfa/onfekafusp alfa (Primary)
- Indications Cutaneous B-cell lymphoma; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Philogen
Most Recent Events
- 11 Dec 2025 Planned End Date changed from 1 Dec 2030 to 1 Feb 2031.
- 11 Dec 2025 Planned primary completion date changed from 1 Dec 2030 to 1 Feb 2031.
- 11 Dec 2025 Planned initiation date changed from 1 Dec 2025 to 1 Feb 2026.